evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

196 questions · 197 findings · 80 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 45 · 22.8%GRADE not reported 15 · 7.6%Very low 42 · 21.3%Low 49 · 24.9%Moderate 36 · 18.3%High 10 · 5.1%

LAMA vs placebo

Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis

LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).

1 finding from 1 review

Summary of findings: tobramycin for inhalation powder vs tobramycin

Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Antibiotic 1 vs antibiotic 2

Adverse events: cotrimoxazole (1) versus cefprozil (2) · children with primarily normal renal tracts who have experienced at least one UTI

Antibiotic 1 showed no clear difference in adverse events: cotrimoxazole (1) versus cefprozil (2) compared with antibiotic 2 (low certainty).

1 finding from 1 review

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review

Antibiotic 1 vs antibiotic 2

Adverse events: nitrofurantoin (1) versus trimethoprim (2) · children with primarily normal renal tracts who have experienced at least one UTI

Antibiotic 1 may leads to higher adverse events: nitrofurantoin (1) versus trimethoprim (2) compared with antibiotic 2 (low certainty).

1 finding from 1 review

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).

1 finding from 1 review